Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Bicuculline methochloride (Alias: (-)-Bicuculline methochloride)

Catalog No. T74112 Copy Product Info
Purity: 99.8%
🥰Excellent
Bicuculline methochloride is a competitive GABAA receptor antagonist and allosteric inhibitor with an IC50 of 1.7 μM. It blocks Ca²⁺-dependent activation of potassium channels, exhibits convulsant activity, and is suitable for epilepsy research.

Bicuculline methochloride

Copy Product Info
🥰Excellent
Catalog No. T74112
Alias (-)-Bicuculline methochloride

Bicuculline methochloride is a competitive GABAA receptor antagonist and allosteric inhibitor with an IC50 of 1.7 μM. It blocks Ca²⁺-dependent activation of potassium channels, exhibits convulsant activity, and is suitable for epilepsy research.

Bicuculline methochloride
Cas No. 38641-83-7
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$34-In Stock
5 mgPreferential-In Stock
10 mgPreferential-In Stock
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.8%
Appearance:Solid
Color:White to Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Bicuculline methochloride is a competitive GABAA receptor antagonist and allosteric inhibitor with an IC50 of 1.7 μM. It blocks Ca²⁺-dependent activation of potassium channels, exhibits convulsant activity, and is suitable for epilepsy research.
Targets&IC50
GABAA:3 μM
In vitro
Bicuculline methochloride (at concentrations of 1 μM and 3 μM) enables gamma-aminobutyric acid (GABA) to reach the maximum response level. This compound induces a parallel rightward shift in the GABA dose-response curve without reducing the maximum response efficacy of GABA. This result indicates that Bicuculline methochloride acts as a competitive antagonist in Xenopus laevis oocytes expressing the human α1β2γ2L subtype of GABAA receptors [3]. When Bicuculline methochloride (at concentrations ranging from 1 to 100 μM) is applied via the external patch method for 2 minutes, it can effectively block the currents of two types of calcium-activated potassium channels in Xenopus laevis oocytes—specifically, the current of apamin-sensitive small-conductance calcium-activated potassium channels (SK2) and the current of apamin-insensitive SK1 channels [4].
In vivo
Bicuculline methochloride can be used for establishing Broussonetia papyrifera in animal epilepsy models. After intracranial injection of bicuculline methochloride (2.5 mM), it causes a significant increase in capillary blood flow in the epileptic focus (i.e., the characteristic region of epileptic seizure in Parazacco spilurus subsp. spilurus), with local blood flow reaching up to 42.5 red blood cells per second. In contrast, the blood flow in regions distant from the epileptic focus is 27.8 red blood cells per second [5].
Disease Modeling Protocol
Focal Epilepsy Model
  • Modeling Mechanism:

    Bicuculline methochloride, as a competitive antagonist of γ-aminobutyric acid A (GABAₐ) receptors, induces epilepsy pathology through multiple mechanisms: ① It blocks GABAₐ receptor-mediated inhibitory synaptic transmission, disrupting the excitability/inhibition balance in the brain, triggering local neuronal overexcitation, and forming focal epileptic seizures; ② It induces hemodynamic changes (increased optical absorption coefficient) in the epileptic focus area, accompanied by abnormal interictal discharges on electroencephalography (EEG), mimicking the core pathological and electrophysiological characteristics of human neocortical epilepsy.

  • Related Products:

    Bicuculline methochloride (T74112)

  • Modeling Method:

    Experimental Subject:

    Rats: Sprague–Dawley (SD), male, adult, weight 240–260 g

    Dosage and Administration Route:

    ① Core modelling: Bicuculline methiodide (1.9 mM), 10 μL/animal, dissolved in saline, stereotaxic injection into right/left parietal cortex or specific brain regions (depth 1–3 mm, e.g., sensory cortex S1, caudate nucleus CPu) as single-dose administration;
    ② Surgical Procedure: Inhalation anaesthesia with isoflurane (4% induction, 1.5% maintenance)+intraperitoneal injection of propofol (1 g/kg). Head fixed in stereotaxic apparatus. Following removal of skull and scalp, microinjection performed at 0.3 μL/min using a microinjector;
    ③ Control procedure: Equal-volume saline administered via identical injection protocol;
    ④ Preparation for detection: Stainless steel screw electrodes implanted in the occipital bone as reference electrodes; DOT/ESL (Diffusion Optical Tomography/Electroencephalogram Source Localisation) probe adhered to cortical surface

    Dosing Frequency and Duration Model:

    Single dose

  • Validation:

    Electrophysiological indicators: EEG recording: Typical epileptiform discharges (increased amplitude, abnormal frequency) appeared after modeling, lasting for more than 6 minutes, while no abnormal discharges were observed in the control group; Optical imaging: DOT detection showed a significant increase in the optical absorption coefficient of the epileptic focus area (P<0.05 vs. resting state), which could accurately locate epileptic foci with an injection depth of 1-3 mm. ESL was used for auxiliary verification, but there was a slight horizontal offset; Specificity verification: When Bicuculline methochloride was injected outside the field of view of the DOT/ESL probe, DOT showed a negative detection (no epileptic focus signal), and ESL may show false positives, confirming the specificity of DOT localization; Behavioral indicators: After modeling, focal limb twitching, stereotyped movements, and other focal epileptic seizure manifestations appeared, without generalized tonic-clonic seizures (consistent with the characteristics of focal epilepsy).

*Precautions: Animals were euthanized humanely in accordance with ethical requirements after the experiment. If long-term observation is required, the frequency of epileptic seizures should be monitored regularly, and euthanasia should be performed promptly if severe and persistent seizures occur.

*References:Yang H,et,al. In vivo imaging of epileptic foci in rats using a miniature probe integrating diffuse optical tomography and electroencephalographic source localization. Epilepsia. 2015 Jan;56(1):94-100.

Synonyms(-)-Bicuculline methochloride
Chemical Properties
Molecular Weight417.84
FormulaC21H20ClNO6
Cas No.38641-83-7
SmilesC[N+]1(C)[C@]([C@]2(C3=C(C(=O)O2)C4=C(C=C3)OCO4)[H])(C5=C(C=C6C(=C5)OCO6)CC1)[H].[Cl-]
Storage & Solubility Information
Storagekeep away from moisture,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 40 mg/mL (95.73 mM), Sonication is recommended.
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM2.3933 mL11.9663 mL23.9326 mL119.6630 mL
5 mM0.4787 mL2.3933 mL4.7865 mL23.9326 mL
10 mM0.2393 mL1.1966 mL2.3933 mL11.9663 mL
20 mM0.1197 mL0.5983 mL1.1966 mL5.9832 mL
50 mM0.0479 mL0.2393 mL0.4787 mL2.3933 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Bicuculline methochloride | purchase Bicuculline methochloride | Bicuculline methochloride cost | order Bicuculline methochloride | Bicuculline methochloride chemical structure | Bicuculline methochloride in vivo | Bicuculline methochloride in vitro | Bicuculline methochloride formula | Bicuculline methochloride molecular weight